Published in Clin Pharm on February 15, 1985
Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother (1989) 1.74
Pharmacists' knowledge and attitudes toward herbal medicine. Ann Pharmacother (2000) 1.80
Catalytic asymmetric cyclopropanation of heteroaryldiazoacetates. J Org Chem (2001) 1.71
Current issues in the treatment of epilepsy. Clin Pharm (1991) 1.47
Measuring the functional status and well-being of patients with migraine headache. Headache (1994) 1.42
Budesonide inhalation powder: a review of its pharmacologic properties and role in the treatment of asthma. Pharmacotherapy (1998) 1.39
The effects of storage and shaking on the settling properties of phenytoin suspension. Neurology (1989) 1.39
Perceptions of pharmacists about adverse effects of corticosteroid therapy: focus on osteoporosis. J Am Pharm Assoc (Wash) (1999) 1.39
Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens. Antimicrob Agents Chemother (1988) 1.23
Studies in the biochemistry of micro-organisms. 108. Metabolites of Alternaria tenuis Auct.: the biosynthesis of tenuazonic acid. Biochem J (1961) 1.10
Isolation and characterisation of hepatotoxins from Penicillum rubrum. J Pharm Pharmacol (1966) 1.08
The role of academia in community-based pharmaceutical care. Pharmacotherapy (1998) 1.07
Pharmacokinetic comparison of three clindamycin phosphate dosing schedules. Drug Intell Clin Pharm (1987) 1.00
Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother (1989) 1.00
A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. J Rheumatol (1996) 0.97
Pertussis toxin inhibits human neutrophil responses mediated by the 42-kilodalton IgG Fc receptor. J Immunol (1988) 0.95
Phenytoin-induced hyperglycemia. Am J Hosp Pharm (1981) 0.94
Analysis of a hospital-based drug information center. Am J Hosp Pharm (1977) 0.93
Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther (1981) 0.92
HLA-DRB1 genotype influences risk for and severity of rheumatoid arthritis. J Rheumatol (1999) 0.92
An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies. Clin Pharmacol Ther (1986) 0.92
Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob Agents Chemother (1986) 0.88
Sucralfate--alternative therapy for peptic-ulcer disease. Clin Pharm (1983) 0.88
Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin. Epilepsy Res (1997) 0.88
Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res (1992) 0.87
Liver function assessment by drug metabolism. Pharmacotherapy (1990) 0.87
Postmarketing drug research and development. Drug Intell Clin Pharm (1987) 0.86
Decreased hepatic clearance of clindamycin in critically ill patients with sepsis. Clin Pharm (1987) 0.85
Stability and cost analysis of clindamycin-gentamicin admixtures given every eight hours. Am J Hosp Pharm (1985) 0.85
Effect of antacid suspension on the pharmacokinetics of ibuprofen. Clin Pharm (1987) 0.83
Physician attitudes toward pharmacists counseling patients on adverse drug reactions. Am J Hosp Pharm (1980) 0.82
Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitin sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions. Am J Hosp Pharm (1985) 0.82
Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Arch Neurol (1996) 0.82
The heart as a target organ of immune injury. Curr Probl Cardiol (1991) 0.82
Methotrexate therapy for autoimmune hearing loss: a preliminary report. Laryngoscope (1994) 0.81
An exploratory study of type II [3 + 4] cycloadditions between vinylcarbenoids and dienes. J Org Chem (2000) 0.80
Monitoring digoxin therapy in two long-term facilities. J Am Geriatr Soc (1981) 0.80
Effect of telephone follow-up on medication compliance. Am J Hosp Pharm (1981) 0.79
Economics of antihypertensive therapy in the elderly. Drugs Aging (2001) 0.79
Home blood glucose monitoring. Ann Pharmacother (1999) 0.79
The impact of disease management on outcomes and cost of care: a study of low-income asthma patients. Inquiry (2000) 0.79
A finite locus effect diffusion model for the evolution of a quantitative trait. J Math Biol (2006) 0.79
Effect of cimetidine on quinidine clearance. Ther Drug Monit (1984) 0.79
Effect of ranitidine and cimetidine on ibuprofen pharmacokinetics. Clin Pharm (1988) 0.79
Lack of ibuprofen secretion into human milk. Clin Pharm (1983) 0.78
Pharmacoeconomic research and clinical trials: concepts and issues. DICP (1989) 0.78
Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures. Neurology (1998) 0.78
Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions. Am J Hosp Pharm (1986) 0.78
The effect of flurbiprofen on steady-state plasma lithium levels. Pharmacotherapy (1997) 0.78
Clindamycin pharmacokinetics and tissue penetration after head and neck surgery. Clin Pharm (1988) 0.78
Update on pharmacotherapy of systemic lupus erythematosus. Am J Health Syst Pharm (1995) 0.78
Effect of antacids on phenytoin bioavailability. Ther Drug Monit (1981) 0.77
Effects of food on valproic acid absorption. Am J Hosp Pharm (1981) 0.77
Effect of erythromycin in patients receiving long-term warfarin therapy. Clin Pharm (1989) 0.77
B lymphocytic clonal expansion in rheumatoid arthritis. J Rheumatol (1996) 0.77
The clinical pharmacist in drug research and development: the publication record. Drug Intell Clin Pharm (1987) 0.77
Effect of ibuprofen on lithium plasma and red blood cell concentrations. Clin Pharm (1986) 0.77
Effects of three antacids on the bioavailability of valproic acid. Clin Pharm (1983) 0.77
Oral neomycin sulfate and erythromycin base before colon surgery: a comparison of serum and tissue concentrations. Pharmacotherapy (1985) 0.77
Use of point-of-service health status assessments by community pharmacists to identify and resolve drug-related problems in patients with musculoskeletal disorders. Pharmacotherapy (2001) 0.76
Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients. Biopharm Drug Dispos (1992) 0.76
Implementing disease management in community pharmacy practice. Clin Ther (1998) 0.76
Removal of prednisone and prednisolone by plasma exchange. Clin Pharm (1984) 0.76
Advances in random matrix theory, zeta functions, and sphere packing. Proc Natl Acad Sci U S A (2000) 0.76
Migraine: a comprehensive review of new treatment options. Pharmacotherapy (1999) 0.75
Improving ambulatory management of asthmatic patients. Am J Med (1997) 0.75
Cyclosporine dosing for RA. Am Pharm (1995) 0.75
Perspective on lamotrigine. Ann Pharmacother (1995) 0.75
Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. J Rheumatol (1998) 0.75
Effects of misoprostol or ranitidine on ibuprofen pharmacokinetics. Clin Pharm (1991) 0.75
Influence of racial differences on effects of ranitidine and cimetidine on ibuprofen pharmacokinetics. Clin Pharm (1989) 0.75
Lack of effect of tacrine administration on the anticoagulant activity of warfarin. J Clin Pharmacol (1995) 0.75
Effect of acute and chronic terfenadine on free and total serum phenytoin concentrations in epileptic patients. Epilepsia (1989) 0.75
Fluvastatin cost considerations. Ann Pharmacother (1994) 0.75
Potential underreporting of intravenous phenytoin adverse events. Ann Pharmacother (1999) 0.75
Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions. Drug Intell Clin Pharm (1986) 0.75
Effects of cimetidine or ranitidine on the pharmacokinetics of flurbiprofen. Clin Pharm (1986) 0.75
The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment. Clin Pharmacol Ther (1996) 0.75
Effect of over-the-counter cimetidine on phenytoin concentrations in patients with seizures. Ann Pharmacother (1999) 0.75
Alpha-methyldopa interference with the phosphotungstate uric acid test. Am J Hosp Pharm (1976) 0.75
Practical considerations in anticonvulsant therapy--Part 1. Am Pharm (1995) 0.75
The effect of age and everyday exercise on steady-state plasma digoxin concentrations. Pharmacotherapy (1995) 0.75
Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles. Drug Intell Clin Pharm (1988) 0.75
Hearing or sight defects and drug use in the elderly. Am J Hosp Pharm (1985) 0.75
Examining nursing personnel costs: controlled versus noncontrolled oral analgesic agents. J Nurs Adm (1989) 0.75
Alprostadil (Prostin VR Pediatric Sterile Solution, The Upjohn Company). Drug Intell Clin Pharm (1982) 0.75
Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers. Biopharm Drug Dispos (1998) 0.75
Spacer inhalers. Arch Intern Med (1986) 0.75
Loss of carbamazepine suspension through nasogastric feeding tubes. Am J Hosp Pharm (1990) 0.75
Cephalosporin antibiotic interference with theophylline assay. Clin Pharm (1983) 0.75
Administering IV nitroglycerin: nursing implications. Dimens Crit Care Nurs (1983) 0.75
Practical considerations in anticonvulsant therapy--Part 2. Am Pharm (1995) 0.75
Steady-state salicylate plasma and urinary metabolite concentrations from plain, buffered, or enteric-coated aspirin. Clin Pharm (1983) 0.75
Compatibility and stability of clindamycin phosphate-aminoglycoside combinations within polypropylene syringes. Drug Intell Clin Pharm (1987) 0.75
Possible diclofenac-quinolone interaction. Clin Pharm (1989) 0.75